Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
HOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE)-Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two hepatitis B virus (HBV) poster presentations at HepDART 2019 being held December 8-12, 2019 in Kauai, Hawaii.
"We are excited to present impressive data on our chimeric antisense oligonucleotide (CASO) program in HBV, including our preclinical candidate, SB 527, at HepDART 2019," commented Dr. Radhakrishnan Iyer, Co-Founder and Chief Scientific Officer of Spring Bank Pharmaceuticals . "Our CASO compounds incorporate the unique feature of having an antisense oligonucleotide linked to an immunomodulator in the same molecule. They are designed to achieve simultaneous HBV gene silencing, to inhibit the production of HBV DNA and all HBV proteins, and activation of innate and adaptive immunity for viral clearance. "Dr. Iyer continued," The data generated to date for SB 527 in non-clinical models demonstrate that our CASOs potently inhibit the production of HBV DNA, as well as HBsAg and HBeAg, the key viral proteins associated with HBV replication. We continue to advance the SB 527 program with the goal of developing a “triplet” therapeutic modality (antisense + immunomodulator + nucleos (t) ide). We believe that the inclusion of an immunomodulator in a triplet therapy regimen provides greater potential for a durable response, increasing the likelihood of achieving a functional cure. "
Spring Bank is developing its CASOs for potential use in the high viral burden chronic HBV patient population as part of a triple therapy regimen, which would include SB 527 plus inarigivir plus a nucleos (t) ide analog. Spring Bank is working in tandem with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to evaluate Spring Bank's CASOs in the HBV mouse model, a well-established preclinical model to assess compound efficacy. Based on the results of these studies, the company plans to conduct IND-enabling toxicology studies in the first half of 2020 with the potential to be IND / CTA-ready in the latter half of 2020.
Presentations on Tuesday, December 10, 2019, from 3:30 – 5:00 (HST), include:
Poster Presentation # P14
Title: "Antisense Oligonucleotide Linked to an Immunomodulatory Dinucleotide are Highly Potent Anti-HBV Agents," by Dr. Lakshmi Bhagat, Discovery Group Leader – Immunology
Summary: Spring Bank ’s lead CASOs potently inhibit HBV DNA, HBsAg and HBeAg via a gene silencing mechanism as well as the intracellular release of an immunomodulator from the CASOs.
Poster Presentation # P5
Title: "The Anti-HBV Dinucleotide Inarigivir is a Novel RIG-I Agonist – MOA Studies," by Dr. Radhakrishnan Iyer, Co-Founder and Chief Scientific Officer
Summary: Preclinical results demonstrate that inarigivir activates the innate immune receptor RIG-I to produce interferons and cytokines for antiviral defense. These preclinical results further validate the mechanism of action and the observed antiviral efficacy of inarigivir in HBV patients.
Following these presentations, the posters will be available on the Publications page of the company ’s website.作者: StephenW 时间: 2019-12-11 13:24
春季银行将在HepDART 2019上展示其针对乙型肝炎的新型嵌合反义寡核苷酸化合物的数据
马萨诸塞州霍普金顿，2019年12月9日（全球新闻）-临床阶段生物制药公司Spring Bank Pharmaceuticals，Inc.（SBPH）是一家临床阶段的生物制药公司，正在开发用于治疗病毒感染，炎性疾病和某些癌症的新型疗法，今天宣布了两项在2019年12月8日至12日在夏威夷考艾岛举行的HepDART 2019上，乙型肝炎病毒（HBV）海报展示。
“我们很高兴在HepDART 2019上展示有关HBV的嵌合反义寡核苷酸（CASO）程序的令人印象深刻的数据，包括我们的临床前候选药物SB 527，” Spring Bank Pharmaceuticals联合创始人兼首席科学官Radhakrishnan Iyer博士评论道。 。 “我们的CASO化合物具有独特的功能，即在同一分子中具有与免疫调节剂相连的反义寡核苷酸。它们旨在实现同时HBV基因沉默，抑制HBV DNA和所有HBV蛋白的产生以及固有和适应性的激活。清除病毒的免疫力。 Iyer继续说道，“迄今为止，在非临床模型中为SB 527生成的数据表明，我们的CASO可以有效抑制HBV DNA以及与HBV复制有关的关键病毒蛋白HBsAg和HBeAg的产生。 SB 527计划旨在开发一种“三联体”治疗方式（反义+免疫调节剂+核苷（t）ide），我们认为在三联体治疗方案中加入免疫调节剂可提供更大的持久应答潜力，从而增加了可能性实现功能性治愈。”